SELLAS Life Sciences Group, Inc.
Activate additional clinical trial sites in the United States, Europe, and Asia
Delivered by the deadline
Under re-examination This entry has been challenged and is being re-checked against the sources.
- Announced
- 11 Aug 2022
- Due
- 31 Dec 2022
- Delivered
- Q2 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company plans to activate additional sites in the United States and several countries in Europe and Asia throughout the remainder of 2022”
What we found
Evidence strength A What the grades mean
SELLAS activated additional clinical trial sites in Europe (Poland, Greece, Hungary) by Q2 2022 and planned further activations in the remainder of 2022.
-
A SEC Filing - SELLAS Business Update Q2 2022
“During the second quarter of 2022, SELLAS continued enrolling patients and activated additional sites in Poland, Greece and Hungary for its registrational global Phase 3 REGAL clinical trial” ✓ confirmed on the page
-
B SELLAS Q1 2022 Business Update
“SELLAS continued to progress enrollment of patients and activation of additional sites in the United States, Europe, and Asia in the first quarter of 2022” not found on the page
-
C SELLAS Life Sciences Q2 2022 Business Update - BioSpace
“During the second quarter of 2022, SELLAS continued enrolling patients and activated additional sites in Poland, Greece and Hungary for its registrational global Phase 3 REGAL clinical” ✓ confirmed on the page
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Activate
- Deliverable
- Additional clinical trial sites
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-SLS-001999 · Corrections policy